Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Bejan-Angoulvant

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Respiratory Medicine and Research|August 11, 2020
Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trialT Bejan-Angoulvant, J-Marc Naccache, A Caille, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|March 1, 2015
[Off-label use of calcium channel blockers as tocolytic agent. CNGOF Workgroup (Short text)]N Winer, T Bejan-Angoulvant, E Clouqueur, et al.
Journal of Human Hypertension|April 18, 2014
Can we identify response markers to antihypertensive drugs? First results from the IDEAL TrialF Gueyffier, F Subtil, T Bejan-Angoulvant, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 21, 2014
[Status and expertise of off-label use of misoprostol in obstetrics and gynecology in France: study by CNGOF (short text)]H Marret, E Simon, G Beucher, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 22, 2015
Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens françaisH Marret, E Simon, G Beucher, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Respiratory Medicine and Research|August 11, 2020
Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trialT Bejan-Angoulvant, J-Marc Naccache, A Caille, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|March 1, 2015
[Off-label use of calcium channel blockers as tocolytic agent. CNGOF Workgroup (Short text)]N Winer, T Bejan-Angoulvant, E Clouqueur, et al.
Journal of Human Hypertension|April 18, 2014
Can we identify response markers to antihypertensive drugs? First results from the IDEAL TrialF Gueyffier, F Subtil, T Bejan-Angoulvant, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 21, 2014
[Status and expertise of off-label use of misoprostol in obstetrics and gynecology in France: study by CNGOF (short text)]H Marret, E Simon, G Beucher, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|February 22, 2015
Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens françaisH Marret, E Simon, G Beucher, et al.
Pageof 3